These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33642513)

  • 1. [Investigation of Leftover Hyperphosphatemia Drugs in Hemodialysis Outpatients].
    Takayama S; Oda M; Saitoh H
    Yakugaku Zasshi; 2021; 141(3):433-440. PubMed ID: 33642513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessing the Effects of Prescription Adjustment and Medication Non-adherence Associated with Medication Efficacy Classifications from Leftover Drugs through the SETSUYAKU-BAG Campaign].
    Kobayashi D; Koyanagi K; Kubota T; Sakamoto Y; Kihara T; Miisho T; Kasaki T; Kunitake M; Takeshita F; Ando E; Baba T; Seo T; Tanaka T; Shimazoe T
    Yakugaku Zasshi; 2018; 138(10):1313-1322. PubMed ID: 30270277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [SETSUYAKU-BAG Campaign--investigation of outpatient's leftover drugs and promotion of proper reuse of leftover drugs to reduce medical expenses].
    Koyanagi K; Kubota T; Kobayashi D; Kihara T; Yoshida T; Miisho T; Saito Y; Uchigoshi H; Takaki J; Seo T; Shimazoe T
    Yakugaku Zasshi; 2013; 133(11):1215-21. PubMed ID: 23978848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Practice for promoting proper use of reusing the leftover medicines in the outpatients of the chronic disease].
    Kutsuma N; Yamaura K; Nakayama M; Namiki M; Akiba K; Kimura S; Ueda H; Numajiri S; Kobayashi D; Morimoto Y
    Yakugaku Zasshi; 2004 Jun; 124(6):355-64. PubMed ID: 15170071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.
    Chiu YW; Teitelbaum I; Misra M; de Leon EM; Adzize T; Mehrotra R
    Clin J Am Soc Nephrol; 2009 Jun; 4(6):1089-96. PubMed ID: 19423571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
    Yin J; Yin J; Lian R; Li P; Zheng J
    BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily dietary phosphorus intake variability and hemodialysis patient adherence to phosphate binder therapy.
    Tao X; Zhang H; Yang Y; Zhang C; Wang M
    Hemodial Int; 2019 Oct; 23(4):458-465. PubMed ID: 31328873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of Using the Adherence Score Sheet According to Application Timing in Improving Medication Adherence in SETSUYAKU-BAG Campaign].
    Kobayashi D; Koyanagi K; Kubota T; Maruyama M; Miisho T; Kaneko E; Kawanami M; Kihara T; Takaki J; Nakashiba T; Nagatomi S; Seo T; Tanaka T; Shimazoe T
    Yakugaku Zasshi; 2018; 138(12):1549-1559. PubMed ID: 30504671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-adherence to drug therapy and drug acquisition costs in a national population--a patient-based register study.
    Hovstadius B; Petersson G
    BMC Health Serv Res; 2011 Nov; 11():326. PubMed ID: 22123025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients.
    Aramwit P; Srisawadwong R; Supasyndh O
    J Nephrol; 2012; 25(3):354-62. PubMed ID: 21748722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients.
    Tsai WC; Yang JY; Luan CC; Wang YJ; Lai YC; Liu LC; Peng YS
    Clin Exp Nephrol; 2016 Oct; 20(5):815-821. PubMed ID: 26658792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
    Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidisciplinary education approach to optimize phosphate control among hemodialysis patients.
    Chan MW; Cheah HM; Mohd Padzil MB
    Int J Clin Pharm; 2019 Oct; 41(5):1282-1289. PubMed ID: 31302884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
    Mukai I; Yoshizawa T; Kumagai J; Takahashi N; Tsuchiya S
    Ther Apher Dial; 2014 Jun; 18 Suppl 1():28-33. PubMed ID: 24953764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentially modifiable factors associated with non-adherence to phosphate binder use in patients on hemodialysis.
    Martins MT; Silva LF; Kraychete A; Reis D; Dias L; Schnitman G; Oliveira L; Lopes GB; Lopes AA
    BMC Nephrol; 2013 Oct; 14():208. PubMed ID: 24090377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.
    El Borolossy R; El Wakeel LM; El Hakim I; Sabri N
    Pediatr Nephrol; 2016 Feb; 31(2):289-96. PubMed ID: 26420678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.